OS stratified by RAS mutation status in a pooled data set. OS stratified by (A) NRAS and (B) KRAS mutant status in a pooled data set including both bortezomib-treated and dexamethasone-treated patients. Each panel shows Cox proportional HR estimates (plus 95% CI) and P values based on a pairwise log-rank test.